A Comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 Assay for the Assessment of Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention

Journal of Clinical Laboratory Analysis

Volumn 26, Issue 4, 2012, Pages 262-266

  Jang, Jiyoung ^a   Lim, Jihyang ^a   Chang, Kiyuk ^a   Kim, Yonggoo ^a   Kim, Myungshin ^a   Il Park, Hae ^a   Kim, Jayoung ^a   Shin, Soyoung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Clopidogrel; Platelet function test; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CORRELATION ANALYSIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADULT; AGED; AGED, 80 AND OVER; CARDIAC CATHETERIZATION; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TICLOPIDINE;

EID: 84863998168     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21515     Document Type: Article

References (28)

1. Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 2003;101:3908-3914.
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-1516.
3. Gurbel PA, Bliden KP, Hiatt BL, O''Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913.
4. Harrison P, Frelinger AL, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007;120:323-336.
5. Young-Guk Ko, Yangsoo Jang. Comparision of 2 point-of-care platelet function tests, VerifyNow Assay and multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart 2011;161:383-390.
6. In-Suk Kim, Young-Hoon Jeong, et al. Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. J Thromb Thrombolysis 2010;30:486-495.
7. Birgit Linnemann, Jan Schwonberg, Rechner AR, Helen Mani, Edelgard Lindhoff-Last. Assessment of clopidogrel non-response by the PFA-100® system using the new test cartridge INNOVANCE® PFA P2Y. Ann Hematol 2010;89:597-605.
8. Van Werkum JW, van der Stelt CA, Seesing TH. A head-to-head comparison between the VerifyNow P2Y12-assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective PCI. J Thromb Haemost 2006;4:2516-2518.
9. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADPdetected by a point-of-care assay: A 12-month follow-up. Circulation 2009;119:237-242.
10. Patti G, Nusca A, Mangiacapra F, Gatto L, D'mbrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO(Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52:1128-1133.
11. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2007;120:311-321.
12. Elsenberg EH, Jochem W, van Werkum, et al. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost 2009;102:719-727.
13. Kwang-Sook Woo, Bo-Ram Kim, Jin-Yeong Han. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests. Korean J Lab Med 2010;30:460-468.
14. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252:233-238.
15. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787.
16. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004;93:456-458.
17. Lepantalo A, Virtanen KS, Heikkila J, Wartiovaara U, Lassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 2004;25:476-483.
18. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005;115:101-108.
19. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
20. Dziewierz A, Dudek D, Heba G, Rakowski T, Mielecki W, Dubiel JS. Inter-individual variability in response to clopidogrel in patients with coronary artery disease. Kardiol Pol 2005;62:108-117.
21. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patientsundergoing percutaneous coronary intervention: The role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33.
22. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-2435.
23. Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. J Cardiovasc Pharmacol Ther 2009;14:157-169.
24. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year followup of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
25. Ajzenberg N, Aubry P, Huisse MG, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: A case-control study. J Am Coll Cardiol 2005;45:1753-1756.
26. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CRESTStudy. J Am Coll Cardiol 2005;46:1827-1832.
27. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000.
28. Breet NJ, Van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-762.